PF-08634404 + Chemotherapy for Non-Small Cell Lung Cancer

This trial aims to explore a new medicine called PF-08634404, an experimental treatment for non-small cell lung cancer (NSCLC). Researchers seek to determine its effectiveness alone or with chemotherapy in individuals with early-stage or locally advanced NSCLC. The trial seeks participants in good physical condition with NSCLC that is either early-stage or locally advanced and may or may not be surgically removable. Participants will be grouped based on their specific type of NSCLC and previous treatments to test different treatment combinations. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss your specific situation with the study team or your doctor.

Previous studies have shown that PF-08634404 has a manageable safety profile, meaning that while some side effects exist, they are generally tolerable. For instance, an earlier study found that when used alone in patients with advanced non-small cell lung cancer, PF-08634404 was effective, with manageable side effects such as fatigue and nausea, common in many cancer treatments.

PF-08634404 is a bispecific antibody that targets proteins involved in cancer cell growth. This type of treatment has been tested in other conditions, suggesting relative safety.

Researchers are excited about PF-08634404 for non-small cell lung cancer (NSCLC) because it offers a unique approach compared to the standard options like surgery, chemotherapy, and immunotherapy. Unlike these treatments, PF-08634404 can be used as a monotherapy in different stages of NSCLC, either alone or in combination with chemotherapy, which might enhance its effectiveness. It specifically targets cancer cells without Actionable Genomic Alterations (AGAs), potentially offering a tailored treatment for patients who don't respond fully to existing therapies. This targeted approach could lead to better outcomes, making it a promising option in the fight against NSCLC.

Research has shown that PF-08634404, one of the treatments in this trial, holds promise for treating non-small cell lung cancer (NSCLC) when used alone. Studies have found that patients with a certain level of PD-L1, a protein on cancer cells, responded well to this treatment. In this trial, some participants will receive PF-08634404 as monotherapy, either as adjuvant or consolidation treatment. Others will receive PF-08634404 combined with chemotherapy as neoadjuvant treatment. When combined with chemotherapy, PF-08634404 has sometimes outperformed standard treatments. This combination has proven to be safe with manageable side effects. This experimental treatment targets PD-1 and VEGF, proteins that aid cancer growth, suggesting it could effectively slow or stop cancer progression.¹³⁴⁶⁷